Heart Failure Clinical Trial
Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
Summary
The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.
Full Description
No additional details provided
Eligibility Criteria
Inclusion Criteria:
At least 18 years of age.
Subject must be able to understand the potential risks and benefits associated with the study.
Baseline systolic blood pressure ≥ 90 mm Hg at the time of enrollment.
Clinical symptoms of dyspnea and laboratory admission BNP levels > 500 pg/mL.
Neither pregnant or breastfeeding at the time of enrollment.
Authorization of patient's enrollment by patient's medical provider.
Exclusion Criteria:
<18 years of age
Denies written informed consent
Pregnant or lactating.
Baseline systolic BP < 90 mmHg or cardiogenic shock
No symptoms of congestion or admission BNP < 500 pg/mL
Known allergy to E.coli-derived products, or any history of anaphylactic reactions to nesiritide.
Receiving dialysis at the time of enrollment.
Serum creatinine > 2.5 mg/dL at the time of enrollment.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Inglewood California, 90301, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.